Dexmedetomidin eller Clonidininfusion til forebyggelse af delirium efter åben hjertekirurgi (ALPHA2PREVENT)
Alfa 2 adrenerge receptoragonister til forebyggelse af delirium og kognitiv tilbagegang efter åben hjertekirurgi (ALPHA2PREVENT): Randomiseret kontrolleret forsøg.
A parallel-group treatment, five-centre, participant and investigator masked, three-arm study to assess the safety and effectiveness of dexmedetomidine or clonidine infusion compared to placebo for the prevention of delirium and cognitive decline in male and female participants aged 70+ scheduled for open heart surgery.
Studieoversigt
Status
Status
Betingelser
Betingelser
Intervention / Behandling
Intervention / Behandling
Detaljeret beskrivelse
Delirium is a major public health concern without therapeutic options. It is an acute disturbance of attention and cognition, precipitated by an acute somatic condition. Delirious patients are often subject to off-label treatment with psychotropic drugs that have dubious effects.
The intravenous alpha-2-adrenergic receptor agonist dexmedetomidine, attenuating sympathetic nervous system activity, shows promise as treatment for delirium, but its use is limited to intensive care units (ICU). Its long-term cognitive effects are unknown. Clonidine is a pharmacodynamically similar drug that can be given orally and has been used for decades as an antihypertensive agent, but is else sparsely studied.
ALPHA2PREVENT will be a three-armed randomised controlled trial to study 1) whether repurposing of clonidine can represent a novel treatment option for delirium, and 2) the possible effects of both dexmedetomidine and clonidine on long-term cognitive trajectories, motor activity patterns, patient rated outcome measures and biomarkers of neuronal injury.
Undersøgelsestype
Undersøgelsestype
Tilmelding (Anslået)
Tilmelding
Fase
Fase
- Fase 4
Kontakter og lokationer
Studiesteder
-
-
-
Bergen, Norge
- Haukeland University Hospital
-
Oslo, Norge
- Oslo University Hospital Ullevål
-
Oslo, Norge
- Oslo University Hospital Rikshospitalet
-
Tromsø, Norge
- University Hospital of North Norway
-
Trondheim, Norge
- St Olav University Hospital
-
-
Deltagelseskriterier
Berettigelseskriterier
Berettigelseskriterier
Aldre berettiget til at studere
Tager imod sunde frivillige
Køn, der er berettiget til at studere
Beskrivelse
Inclusion Criteria:
Participants are eligible to be included in the study only if all of the following criteria apply:
-
Participant must be ≥70 years old at the time of signing the informed consent.
-
Participant must be accepted for cardiac surgery with cardiopulmonary bypass. The surgical procedures may constitute 1) coronary bypass grafting, 2) tricuspid, mitral, or aortic valve replacement or repair, 3) surgery on the ascending aorta, and 4) the combination any of these procedures.
-
Participant must be capable of giving signed informed consent.
Exclusion Criteria:
Participants are excluded from the study if any of the following criteria apply:
-
Preoperative delirium
-
Known hypersensitivity to the active ingredient or components of the product
-
Bradycardia due to sick-sinus-syndrome, 2nd or 3rd degree AV-block (if not treated with pacemaker) or any other reason causing HR <50 bpm at time of inclusion
-
Uncontrolled hypotension
-
Ischemic stroke or transitory ischemic attack the last month or critical peripheral ischemia
-
Acute coronary syndrome last 24 hours. Acute coronary syndrome is defined according to international guidelines
-
Left ventricular ejection fraction < 40%
-
Severe renal impairment (estimated GFR <20ml/min) or expected requirement for renal replacement therapy
-
Severe hepatic dysfunction (liver enzyme three times the upper limit of normal together with a serum albumin concentration below the normal reference limit)
-
Reduced peripheral autonomous activity (e.g. spinal cord injury)
-
Current use of tricyclic antidepressants, monoamine reuptake inhibitors or ciclosporin
-
Endocarditis or sepsis
-
Pheochromocytoma
-
Planned deep hypothermia and circulatory arrest
-
Emergency surgery, defined as less than 24 hours from admission to surgery
-
Previously included in this study
-
Not speaking or reading Norwegian
-
Any other condition as evaluated by the treating physician
Studieplan
Hvordan er undersøgelsen tilrettelagt?
Design detaljer
- Primært formål: Forebyggelse
- Tildeling: Randomiseret
- Interventionel model: Parallel tildeling
- Maskning: Firedobbelt
Antal våben
Våben og indgreb
Deltagergruppe / ArmDeltagergruppe / Arm |
Intervention / BehandlingIntervention / Behandling |
|---|---|
|
Eksperimentel: Dexmedetomidine (D)
Continuous intravenous infusion of dexmedetomidine 0.4 μg/kg/hour from the start of cardiopulmonary bypass and during surgery, followed by 0.2 μg/kg/hour until discharge from the ICU or 24 hours postoperatively, whichever happens first. |
Continous intravenous infusion
Andre navne:
|
|
Eksperimentel: Clonidine (C)
Continuous intravenous infusion of clonidine 0.4 μg/kg/hour from the start of cardiopulmonary bypass and during surgery, followed by 0.2 μg/kg/hour until discharge from the ICU or 24 hours postoperatively, whichever happens first. |
Continous intravenous infusion
Andre navne:
|
|
Placebo komparator: Placebo (P)
Continuous intravenous infusion of saline 0.4 μg/kg/hour from the start of cardiopulmonary bypass and during surgery, followed by 0.2 μg/kg/hour until discharge from the ICU or 24 hours postoperatively, whichever happens first. |
Continous intravenous infusion NaCl
Andre navne:
|
Hvad måler undersøgelsen?
Primære resultatmål
Primære resultatmål
Resultatmål |
Foranstaltningsbeskrivelse |
Tidsramme |
|---|---|---|
|
Postoperative delirium
Tidsramme: Up to 7 days
|
Cumulative incidence of postoperative delirium, as diagnosed according to Diagnostic and Statistical Manual of Mental Disorders, 5th edition (DSM-5) criteria |
Up to 7 days
|
Sekundære resultatmål
Sekundære resultatmål
Resultatmål |
Foranstaltningsbeskrivelse |
Tidsramme |
|---|---|---|
|
Incidence of coma
Tidsramme: Up to 7 days
|
Incidence of coma, as measured by Richmond Agitation Sedation Scale (-5 to +5) |
Up to 7 days
|
|
Incidence of death, coma or postoperative delirium
Tidsramme: Up to 7 days
|
Incidence of death, coma or postoperative delirium, as described above |
Up to 7 days
|
|
Number of delirium days postoperatively
Tidsramme: Up to 7 days
|
Number of delirium days postoperatively, as diagnosed according to DSM-5 criteria |
Up to 7 days
|
|
Delirium severity
Tidsramme: Up to 7 days
|
Delirium severity, as measured by Confusion Assessment Method for Intensive Care Units-7 (CAM-ICU)-7 |
Up to 7 days
|
|
Motor activity patterns
Tidsramme: 6 months
|
Motor activity patterns, assessed with body worn accelerometers |
6 months
|
|
Change in cognitive function between inclusion and after 1 and 6 months
Tidsramme: 6 months
|
Change in cognitive function between inclusion and after 1 and 6 months, as graded by Montreal Cognitive Assessment (MoCA), 10-words memory task from The Consortium Establish a Registry for Alzheimer's Disease (CERAD), digit span tests, Trail making tests (TMT) A and B, semantic and phonemic verbal fluency, and measured repeatedly preoperatively and 1 and 6 months after surgery |
6 months
|
|
Change in patient rated health status between inclusion and after 1 and 6 months
Tidsramme: 6 months
|
Change in patient rated health status between inclusion and after 1 and 6 months, as assessed by the EQ-5D-5L questionnaire preoperatively and 1 and 6 months postoperatively |
6 months
|
|
Serum concentrations of NFL and p-tau181
Tidsramme: 5 days postoperatively
|
Comparison to inclusion of serum concentrations of neurofilament light (NFL) and p-tau181 1, 3 and 5 days postoperatively |
5 days postoperatively
|
|
Estimate associations between frailty and the other endpoints
Tidsramme: 6 months
|
Estimate associations between frailty and the other endpoints, as described above |
6 months
|
|
Safety and tolerability
Tidsramme: 6 months
|
Safety and tolerability as determined by the numbers of Adverse Events (AEs), serious AEs (SAEs) and suspected unexpected serious adverse reactions (SUSARs), and vital signs; blood pressure (BP), heart rate (HR), peripheral oxygen saturation (SpO2) postoperatively |
6 months
|
|
Interaction between preoperative frailty and treatment on delirium and the other endpoints
Tidsramme: 6 months
|
Interaction between preoperative frailty and treatment on delirium and the other endpoints, as described above |
6 months
|
|
Change in frailty status between inclusion and after 1 and 6 months
Tidsramme: 6 months
|
Change in frailty status between inclusion and after 1 and 6 months, as graded by the frailty index (FI) and essential frailty toolset (EFT) (section 8.1.3), and measured repeatedly preoperatively and 1 and 6 months after surgery |
6 months
|
|
Comparison of change in frailty status between inclusion and after 1 and 6 months
Tidsramme: 6 months
|
Comparison of change in frailty status between inclusion and after 1 and 6 months (as described above) between patients with or without postoperative delirium. |
6 months
|
Andre resultatmål
Andre resultatmål
Resultatmål |
Foranstaltningsbeskrivelse |
Tidsramme |
|---|---|---|
|
Additional biomarkers
Tidsramme: 5 days postoperatively
|
Additional biomarkers of neural injury, inflammation or neurotransmission may be explored |
5 days postoperatively
|
Samarbejdspartnere og efterforskere
Sponsor
Sponsor
Samarbejdspartnere
Samarbejdspartnere
Efterforskere
Efterforskere
- Ledende efterforsker: Bjørn Erik Neerland, PhD, Oslo University Hospital
Publikationer og nyttige links
Datoer for undersøgelser
Studer store datoer
Studiestart (Faktiske)
Studiestart
Primær færdiggørelse (Faktiske)
Primær færdiggørelse
Studieafslutning (Anslået)
Studieafslutning
Datoer for studieregistrering
Først indsendt
Først indsendt
Først indsendt, der opfyldte QC-kriterier
Først indsendt, der opfyldte QC-kriterier
Først opslået (Faktiske)
Først opslået
Opdateringer af undersøgelsesjournaler
Sidste opdatering sendt (Faktiske)
Sidste opdatering sendt
Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier
Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier
Sidst verificeret
Sidst verificeret
Mere information
Begreber relateret til denne undersøgelse
Yderligere relevante MeSH-vilkår
- Neurologiske manifestationer
- Sygdomme i nervesystemet
- Psykiske lidelser
- Patologiske processer
- Forvirring
- Neuroadfærdsmæssige manifestationer
- Neurokognitive lidelser
- Kognitionsforstyrrelser
- Patologiske tilstande, tegn og symptomer
- Tegn og symptomer
- Skrøbelighed
- Delirium
- Kognitiv dysfunktion
- Heterocykliske forbindelser, 1-ring
- Heterocykliske forbindelser
- Azoler
- Imidazoler
- Uorganiske kemikalier
- Klorforbindelser
- Natriumforbindelser
- Chlorider
- Hydrochlorsyre
- Imidazoliner
- Dexmedetomidin
- Clonidin
- Natriumchlorid
Andre undersøgelses-id-numre
Andre undersøgelses-id-numre
- 2021-001645-12
- 2021-001645-12 (EudraCT nummer)
Plan for individuelle deltagerdata (IPD)
Planlægger du at dele individuelle deltagerdata (IPD)?
Lægemiddel- og udstyrsoplysninger, undersøgelsesdokumenter
Studerer et amerikansk FDA-reguleret lægemiddelprodukt
Studerer et amerikansk FDA-reguleret enhedsprodukt
produkt fremstillet i og eksporteret fra U.S.A.
Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .